EBS

Emergent is a post-crisis turnaround the market is still pricing for distress. After the losses tied to its COVID manufacturing debacle (net income of -$761M in FY2023 and -$191M in FY2024), FY2025 swung to $52.6M of net income (+127.6%), operating income of $100M (+192.1%) and diluted EPS of $0.93. Crucially the cash is real, not accounting: operating cash flow was $171M against only $13.8M of capex, i.e. ~$157M of free cash flow against a $429M market cap — a free-cash-flow yield near 37% on a stock trading at 8.9x earnings and 0.6x sales. Management is acting like the equity is cheap too: they bought back 863,054 shares in Q4 2025 at $9.45–$11.93, cut shares outstanding 4.7%, and in February 2026 re-authorized a fresh $50M program through March 2027. At $8.28 the buyer today is paying below both the company's own recent repurchase prices and the $10.99 February close cited in the 10-K.

The balance sheet has been repaired in lockstep. Cash more than doubled to $205M (+106.4%), long-term debt fell 13.8% to $572M with no current maturities, and liquidity is fortress-like — current assets of $663M cover current liabilities of $132M five times over. Equity grew 8.2% to $523M, leaving liabilities/equity at a manageable 1.52x, and ROE printed 10.1%. This is no longer a going-concern story; it is a cash-generative, deleveraging specialty-pharma name.